Bio-Rad Labs (BIO) Tops Q2 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts BIO Hot Sheet
Price: $359.32 -1.15%
EPS Growth %: -1.3%
Financial Fact:
Net income attributable to Bio-Rad: 18.01M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -1.3%
Financial Fact:
Net income attributable to Bio-Rad: 18.01M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $3.00, $0.32 better than the analyst estimate of $2.68. Revenue for the quarter came in at $681.1 million versus the consensus estimate of $697.96 million.
For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's capital-raising plans expose a major weakness in the AI boom
- Nokia shares recover after analysts call selloff overdone
- StoneX Reiterates Hold Rating on Spotify (SPOT)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
